EndoGastric raises $30M surgical devices

Lead investors Canaan Partners and Radius Ventures led a Series F round of financing that pumped $30 million into EndoGastric Solutions. Advanced Technology Ventures, MPM Capital, Foundation Medical Partners, Chicago Growth Partners and De Novo Ventures also participated.

EndoGastric has two products, EsophyX and StomaphyX, which use the company's natural orifice surgery (NOS) platform technology to treat gastrointestinal problems. The devices enter the body through the mouth rather than through an incision, something that is easier for patients and leads to shorter hospital stays and faster recovery. According to a release, EndoGastric plans to use the funding to increase the commercial presence of EsophyX and StomaphyX, and conduct clinical trials for other diseases.

"Over the past two years, the EsophyX and StomaphyX product platforms have been embraced with a high level of enthusiasm by the surgeon community, resulting in 100 percent revenue growth and 150 percent utilization growth in 2009 and thus far in 2010," notes EndoGastric CEO Thierry Thaure. "Our goal is to establish NOS as the standard of care for patients with chronic acid reflux whose clinical needs are not met with medical management, and in the future, patients who suffer from obesity."

- check out the EndoGastric release

PLUS: Aptus Endosystems has raised $15 million Series AA financing with help from lead investors U.S. Venture Partners and Longitude Capital. The company is developing technology for endovascular aneurysm repair. Aptus release

ALSO: ClearCount Medical Solutions has closed a $5M Series B financing round. The company will use the funds to drive market penetration and research and development of its RFID-based solutions for hospital patient safety applications. ClearCount release

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.